Discovery of 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat) and congeners as highly potent and selective inhibitors of aldose reductase for treatment of chronic diabetic complicationsVan Zandt, M.C., Jones, M.L., Gunn, D.E., Geraci, L.S., Jones, J.H., Sawicki, D.R., Sredy, J., Jacot, J.L., Dicioccio, A.T., Petrova, T., Mitschler, A., Podjarny, A.D.
(2005) J Med Chem 48: 3141-3152
- PubMed: 15857120
- DOI: https://doi.org/10.1021/jm0492094
- Primary Citation of Related Structures:
- PubMed Abstract:
Recent efforts to identify treatments for chronic diabetic complications have resulted in the discovery of a novel series of highly potent and selective 3-[(benzothiazol-2-yl)methyl]indole-N-alkanoic acid aldose reductase inhibitors. The lead candidate, 3-[(4,5,7-trifluorobenzothiazol-2-yl)methyl]indole-N-acetic acid (lidorestat, 9) inhibits aldose reductase with an IC(50) of 5 nM, while being 5400 times less active against aldehyde reductase, a related enzyme involved in the detoxification of reactive aldehydes. It lowers nerve and lens sorbitol levels with ED(50)'s of 1.9 and 4.5 mg/kg/d po, respectively, in the 5-day STZ-induced diabetic rat model. In a 3-month diabetic intervention model (1 month of diabetes followed by 2 months of drug treatment at 5 mg/kg/d po), it normalizes polyols and reduces the motor nerve conduction velocity deficit by 59% relative to diabetic controls. It has a favorable pharmacokinetic profile (F, 82%; t(1/2), 5.6 h; Vd, 0.694 L/kg) with good drug penetration in target tissues (C(max) in sciatic nerve and eye are 2.36 and 1.45 mug equiv/g, respectively, when dosed with [(14)C]lidorestat at 10 mg/kg po).
The Institute for Diabetes Discovery, LLC, 23 Business Park Drive, Branford, Connecticut 06405, USA. michael.vanzandt@ ipd-discovery.com